Tuberc Respir Dis > Accepted Articles
DOI:    [Accepted]
Published online October 26, 2022.
Update on adjuvant treatment in resectable NSCLC and potential biomarkers predicting postoperative relapse
Jeong Uk Lim, MD, PhD
Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Correspondence:  Jeong Uk Lim,
Received: 16 May 2022   • Revised: 18 August 2022   • Accepted: 21 October 2022
Significant proportion of patients with non-small cell lung cancer (NSCLC) are diagnosed in early and resectable stage. Despite use of platinum-based adjuvant chemotherapy, there was only marginal increase in overall survival, and 15% decrease in relapse. With the advents of immunotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), landscape of adjuvant treatment in completely resectable NSCLC is changing. Postoperative radiotherapy can be beneficial to patients who underwent surgical resection in certain clinical settings. In addition, new biomarkers that predict efficacy of EGFR TKI and immunotherapy as adjuvant treatment are also necessary. In this review, recent updates in adjuvant treatment in resectable NSCLC were briefly explained.
METRICS Graph View
  • 0 Crossref
  •   Scopus
  • 368 View
  • 33 Download
Related articles

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2022 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next